Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.

Ritlecitinib can help about 14,000 people with severe hair loss.

Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

The medication combination did not affect glucose tolerance but increased some cholesterol levels due to its estrogen component.

Flutamide, delivered by solid lipid nanoparticles, could potentially treat hair loss.

The method produces finasteride with a 92% yield.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Polygoni Cuspidati Rhizoma et Radix contains compounds that inhibit certain enzymes.

A reliable method was developed to accurately measure tamsulosin hydrochloride and finasteride in tablets.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

A man with both Klinefelter syndrome and primary hyperparathyroidism showed a rare combination of symptoms and genetic patterns.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

RUM-loaded SLN shows promise for treating acne and hair loss topically.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.

KY19382 helps regrow hair and create new hair follicles.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.